Professor Kamala Thriemer
Principal Research Fellow
Qualifications:
PhD, University Antwerp, Belgium, 2013; Master of Public Health, University Liverpool, UK, 2011; Medical degree, Medical University Vienna, Austria, 2005
Approved level of HDR supervision at Charles Darwin University:
Primary supervisor for PhD
Location:
Darwin - Royal Darwin Hospital campus
Biography:
Kamala Thriemer is a clinical researcher committed to public health and tropical medicine. She holds a Medical Degree, a Master of Public Health and a PhD. She has more than fifteen years’ field experience in Africa and Asia, coordinating large scale and multi-centred clinical trials to inform treatment of infectious diseases. Her research focuses on optimising the treatment of P. vivax and developing public health strategies for malaria elimination. Her research program spans from clinical trials and epidemiological studies to policy and implementation research. She also teaches in Menzies Postgraduate Public Health programs for Charles Darwin University.
Kamala graduated from the Medical University Vienna (MUV), Austria in 2005 where she first began researching antimalarial drug resistance in Thailand and Bangladesh. Kamala graduated with a Master of Public Health from the University of Liverpool in 2011 and received her PhD degree from the University Antwerp, Belgium.
She is an Associate Member of the Australian Academy of Health and Medical Sciences.
- EFFORT clinical trial: Effectiveness of tafenoquine and primaquine
- Optimizing the radical cure of P.vivax malaria (OPRA)
- ACROSS Study: Populations at risk of malaria and drug induced haemolysis
- PRIMA clinical trial: Universal Radical Cure of P. vivax malaria
- SIRIN clinical trial: Radical cure of P. vivax malaria in Nepal
- IMPROV Study: Short-course treatment regimen for radical cure of P. vivax malaria
- Asia Pacific Malaria elimination network (APMEN).
- TADORE study: A revised tafenoquine dose to improve radical cure for vivax malaria
- Thriemer K, Degaga T, Alam MS, Adhkari B, Tripura R, Hossain MS, Christian M, Ghanchi NK, Mnjala H, Weston S, Ley B, Rumaseb A, Tadesse D, Teferi T, Yilma D, Lee G, Unger H, Sutanto I, Pasaribu AP, Ghimire P, Beg MA, Price RN. Adapting international clinical trials during COVID-19 and beyond. Clin Trials. 2023 Feb 11:17407745231154215. doi: 10.1177/17407745231154215
- Thriemer K, Degaga T, Christian M, Alam MS, Ley B, Hossain MS, Kibria MG, Teferi T, Tadesse D, Weston S, Karahalios A, Rajasekhar M, Simpson JA, Rumaseb A, Mnjala H, Lee G, Woyessa A, Anose RT, Kidane FG, Baird K, Sutanto I, Hailu A, Price RN. Reducing the risk of P. vivax after falciparum infections in co-endemic areas - a randomized controlled trial. Trials. 2022 May 18;23(1):416. doi: 10.1186/s13063-022-06364-z.
- Poespoprodjo JR, Burdam FH, Candrawati F, Ley B, Meagher N, Kenangalem E, Indrawanti R, Trianty L, Thriemer K, Price DJ, Simpson JA, Price RN. Supervised versus unsupervised primaquine radical cure for the treatment of falciparum and vivax malaria in Papua, Indonesia: a cluster randomised, controlled, open-label superiority trial. Lancet Infect Dis. 2022 Mar;22(3):367-376. doi: 10.1016/S1473-3099(21)00358-3. Epub 2021 Oct 25.
- Ruwanpura VH, Neukom J, Grietens KP, Price RN, Lynch CA, Thriemer K. Opening the policy blackbox: unravelling the process for changing national diagnostic and treatment guidelines for vivax malaria in seven countries. Malar J. 2021 Oct 30;20(1):428. doi: 10.1186/s12936-021-03959-w.
- Thriemer, K., Ley, B., von Seidlein, L. Towards the elimination of Plasmodium vivax malaria: implementing radical cure. PLoS Med, 2021 Apr 23;18(4):e1003494. doi: 10.1371/journal.pmed.1003494.
- Taylor, W.R.J.*, Thriemer, K.*, von Seidlein, L., Yuentrakul, P., Assawariyathipat, T., Assefa, A., et al. (2019). Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial. Lancet, 394 (10202), 929-938. doi: 10.1016/S0140-6736(19)31285-1.
- Commons, R.J., Simpson, K.A., Thriemer ,K., Hossain, M.S., Douglas, N.M., Humphreys, G.S., et al. (2019) Risk of Plasmodium vivax parasitaemia after Plasmodium falciparum infection: a systematic review and meta-analysis. Lancet Infect Dis,19(1), 91-101. doi: 10.1016/S1473-3099(18)30596-6.
- Abreha, T.*, Hwang, J.*, Thriemer, K.* , Tadesse, Y., Girma, S., Melaku, Z., et al. (2018) Comparison of artemether-lumefantrine and chloroquine with and without primaquine for the treatment of Plasmodium vivax infection in Ethiopia: A randomized controlled trial. PLOS Medicine 15(10): e1002677. https://doi.org/10.1371/journal.pmed.1002677
- PREGACT Study Group, Pekyi, D., Ampromfi, A.A., Tinto, H., Traoré-Coulibaly, M., Tahita, M.C., et al. (2016). Four Artemisinin-Based Treatments in African Pregnant Women with Malaria. New England Journal of Medicine, 374(10), 913-27. doi: 10.1056/NEJMoa1508606.
- Thriemer, K., Hong, N.V., Rosanas-Urgell, A., Phuc, B.Q., Ha, D.M., Pockele, E., et al. (2014). Delayed parasite clearance after treatment with dihydroartemisinin-piperaquine in Plasmodium falciparum malaria patients in Central Vietnam. Antimicrobial Agents and Chemotherapy, 58(12), 7049-55. pii: AAC.02746-14.
* shared first authorship